Lucinactant Brand Name– SURFAXIN
What is Lucinactant
Lucinactant is a synthetic surfactant replacement therapy indicated for the prevention of respiratory distress syndrome (RDS) in premature neonates.
Lucinactant contains the proprietary peptide ‘sinapultide’, which was designed to mimic the human surfactant protein B (SP-B).
The product contains 4 active pharmaceutical ingredients: a novel peptide, a fatty acid, and 2 phospholipids.
Results from a clinical trial in premature infants with RDS (n = 1036) indicated that infants treated with lucinactant demonstrated a statistically significant improvement in RDS at 24 hours (39% vs 47%; p < 0.01) and RDS-related mortality through day 14 (5% vs 9%; p < 0.01) as compared with those infants treated with another synthetic surfactant, colfosceril.
Lucinactant was investigated for the treatment of acute respiratory distress syndrome (ARDS) in adults; however, due to an increased incidence of serious adverse events (death, multi-organ failure, sepsis, anoxic encephalopathy, renal failure, hypoxia/decreased oxygen saturation, pneumothorax, hypotension, and pulmonary embolism), it is not indicated for the treatment of ARDS in adults.
Lucinactant was approved by the FDA in March 2012 for the prevention of RDS in premature neonates
- neonatal respiratory distress syndrome prophylaxis
For neonatal respiratory distress syndrome prophylaxis in premature neonates
- metabolic acidosis
- arterial blood gases (ABGs)
- chest x-ray
- requires an experienced clinician
- respiratory distress syndrome
No information is available regarding drug interactions associated with Lucinactant –